Search Results
Jun 03, 2026, 16:15 ET Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential
More news about: Karyopharm Therapeutics Inc.
Jun 03, 2026, 11:17 ET Green Logistics Market to Cross USD 2 Trillion by 2031 with Road Transport Commanding 71.30% Market Share, Says Mordor Intelligence
CorporationGEODISHellmann Worldwide LogisticsKuehne + Nagel International AGNippon ExpressCEVA LogisticsXPO LogisticsDSV A/SYusen Logistics Co., Ltd.Bollore LogisticsAl-Futtaim LogisticsMahindra Logistics Ltd.Americold
More news about: Mordor Intelligence Private Limited
Jun 02, 2026, 10:02 ET Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
(2023)About XPOVIO® (selinexor)XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved and marketed by Karyopharm in the U.S. in multiple oncology
More news about: Karyopharm Therapeutics Inc.
Jun 02, 2026, 08:59 ET Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
XPOVIO® (selinexor)XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved and marketed by Karyopharm in the U.S. in multiple oncology
More news about: Karyopharm Therapeutics Inc.
Jun 02, 2026, 08:45 ET Molex Unveils Multi-Channel Liquid Cooled Busbar Capability at Computex 2026 to Power Next-Generation AI Data Centers
constraints.448G high-speed connectivity: Solutions designed to support next-gen data transmission within AI servers.CPO, CPC and XPO connectivity portfolio: Co-packaged and optical solutions that support scale-up architectures, enabling higher interconnect density while reducing
More news about: Molex Incorporated
Jun 01, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential
More news about: Karyopharm Therapeutics Inc.
Jun 01, 2026, 07:30 ET Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing
More news about: Karyopharm Therapeutics Inc.
May 30, 2026, 15:25 ET Menarini Group 於 2026 年美國臨床腫瘤學會 (ASCO) 週年大會上發表第 1b/2 期 ELEVATE 研究中，使用埃拉司群 (Elacestrant) 聯合卡帕塞替尼 (Capivasertib) 治療 ER+、HER2- 轉移性乳癌 (mBC) 患者的最新數據。
亦在美國、歐洲及其他全球地區銷售他格索芙 (tagraxofusp-erzs)。這是一種針對 CD123 的新型標靶藥物，用於治療母細胞性漿細胞樣樹突細胞腫瘤 (BPDCN) 患者，即侵襲性血液癌症。 此外，Stemline 在歐洲銷售塞利尼索 (selinexor)，這是一種用於治療多發性骨髓瘤的 XPO1 (出口蛋白 1) 抑制劑。 該公司亦分別針對乳癌及血液惡性腫瘤適應症，進行多項有關埃拉司群和他格索芙的適應症擴展研究，並且擁有龐大的臨床研發管線，當中包括多種處於不同開發階段、針對多種實體腫瘤和血液惡性腫瘤的其他候選藥物。
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:09 ET Il Gruppo Menarini presenta nuovi dati dello studio ELEVATE di fase 1b/2 su elacestrant in combinazione con capivasertib in pazienti con carcinoma mammario metastatico (mBC) ER+, HER2- in occasione del Congresso annuale 2026 dell'American Society of Clinical Oncology (ASCO)
ematologico aggressivo, negli Stati Uniti, in Europa e in altre regioni del mondo. Inoltre, Stemline commercializza in Europa selinexor, un inibitore di XPO1 per il mieloma multiplo. L'azienda sta inoltre conducendo diversi studi di estensione dell'indicazione con elacestrant e tagraxofusp, rispettivamente
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:07 ET Menarini Group apresenta novos dados do estudo ELEVATE de Fase 1b/2 sobre o elacestranto em associação com o capivasertibe em pacientes com câncer de mama metastático (CMm) ER+, HER2- no Congresso Anual de 2026 da American Society of Clinical Oncology (ASCO)
câncer hematológico agressivo, nos Estados Unidos, Europa e outras regiões globais. Além disso, a Stemline comercializa o selinexor, um inibidor de XPO1 para mieloma múltiplo, na Europa. A empresa também está conduzindo vários estudos de expansão de rótulo com elacestranto e tagraxofusp em indicações
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:02 ET Menarini Group presenta nuevos datos del ensayo ELEVATE de fase 1b/2 de elacestrant combinado con capivasertib en pacientes con cáncer de mama metastásico (CMM) con receptores de estrógeno positivos (ER+) y HER2 negativo (HER2-) en la reunión anual de la Sociedad Estadounidense de Oncología Clínica (ASCO) de 2026
cáncer hematológico agresivo, en Estados Unidos, Europa y otras regiones del mundo. Por otra parte, Stemline comercializa selinexor, un inhibidor de XPO1 para el mieloma múltiple, en Europa. Adicionalmente, la empresa también lleva a cabo múltiples estudios de expansión de etiquetas con elacestrant y
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 17:06 ET Die Menarini Group präsentiert auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) neue Daten aus der Phase-1b/2-Studie ELEVATE zu Elacestrant in Kombination mit Capivasertib bei Patientinnen mit ER-positivem, HER2-negativem metastasiertem Brustkrebs (mBC)
hämatologischen Krebserkrankung, in den Vereinigten Staaten, Europa und anderen globalen Regionen. Darüber hinaus vertreibt Stemline in Europa Selinexor, einen XPO1-Inhibitor zur Behandlung des multiplen Myeloms. Das Unternehmen führt außerdem mehrere Studien zur Erweiterung der Indikation mit Elacestrant und Tagraxofusp
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 11:40 ET Le Groupe Menarini présente de nouvelles données de l'étude ELEVATE sur l'association de l'élacestrant et du capivasertib
cellules dendritiques plasmacytoïdes (BPDCN), un cancer hématologique agressif. En outre, Stemline commercialise en Europe le sélinexor, un inhibiteur de XPO1 pour le traitement du myélome multiple. La société mène également de multiples études d'extension d'étiquette avec l'élacestrant et le tagraxofusp dans
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 10:13 ET 메나리니 그룹, 2026 미국임상종양학회(ASCO) 연례회의에서 ER+, HER2- 전이성 유방암(mBC) 환자를 대상으로 엘라세스트란트와 카피바서팁 병용요법을 평가한 1b/2상 ELEVATE 시험 신규 데이터 발표
스템라인은 또한 공격성 혈액암인 모구 형질세포양 수지상세포 종양(BPDCN) 환자를 대상으로 CD123을 표적으로 하는 새로운 표적치료제 타그락소푸스프-erzs를 미국, 유럽 및 기타 글로벌 지역에서 상용화하고 있다. 이 밖에도 스템라인은 유럽에서 다발골수종 치료를 위한 XPO1 억제제 셀리넥서를 상용화하고 있다. 회사는 또한 각각 유방암 및 혈액암 적응증에서 엘라세스트란트와 타그락소푸스프의 여러 적응증 확대 시험을 진행 중이며, 다양한 고형암 및 혈액암을 대상으로 여러 개발 단계에 있는 추가 신약 후보물질의 광범위한 임상 파이프라인을 보유하고
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 05:23 ET Menarini Group presenta nuevos datos del estudio ELEVATE de elacestrant en combinación con capivasertib
cáncer hematológico agresivo, en Estados Unidos, Europa y otras regiones del mundo. Además, Stemline comercializa en Europa selinexor, un inhibidor de XPO1 para el mieloma múltiple. La compañía también está llevando a cabo varios estudios de ampliación de indicaciones con elacestrant y tagraxofusp para
More news about: Menarini Industrie Farmaceutiche Riunite
May 28, 2026, 12:46 ET Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
(BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast
More news about: Menarini Industrie Farmaceutiche Riunite
May 28, 2026, 07:30 ET Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference
first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential
More news about: Karyopharm Therapeutics Inc.
May 27, 2026, 09:26 ET Echo Global Logistics' Announces 2025 LTL Carrier of the Year Awardees
Congratulations to the following winners:National LTL Carrier of the YearXPORegional LTL Carrier of the YearPitt OhioPlatinum AwardsAAA CooperDaytonSoutheasternWard"We're
More news about: Echo Global Logistics
May 26, 2026, 17:12 ET 美納里尼集團於 2026 年美國臨床腫瘤學會 (ASCO) 年會上發佈新數據
Stemline 亦在美國、歐洲及其他全球地區銷售他格索芙 (tagraxofusp-erzs)。這是一種針對 CD123 的新型標靶藥物，用於治療母細胞性漿細胞樣樹突細胞腫瘤 (BPDCN) 患者，即侵襲性血液癌症。 此外，Stemline 在歐洲銷售 塞利尼索，這是一種用於治療多發性骨髓瘤的 XPO1 (出口蛋白 1) 抑制劑。 該公司亦分別針對乳癌及血液惡性腫瘤適應症，進行多項有關埃拉司群和他格索芙的適應症擴展研究，並且擁有龐大的臨床研發管線，當中包括多種處於不同開發階段、針對多種實體腫瘤和血液惡性腫瘤的其他候選藥物。
More news about: Menarini Industrie Farmaceutiche Riunite
May 26, 2026, 16:45 ET Menarini Group annuncia nuovi dati alla riunione annuale dell'American Society of Clinical Oncology (ASCO) 2026
ematologico aggressivo, negli Stati Uniti, in Europa e in altre regioni del mondo. Inoltre, in Europa, Stemline commercializza selinexor, un inibitore di XPO1 per il mieloma multiplo. L'azienda sta anche conducendo studi multipli di espansione delle etichette con elacestrant e tagraxofusp, rispettivamente
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 11:56 ET 메나리니 그룹, 2026 미국임상종양학회(ASCO) 연례회의에서 새로운 데이터 발표
내분비 요법제다. 또한 스템라인은 미국, 유럽 및 기타 글로벌 지역에서 공격성 혈액암인 모구성 형질세포양 수지상세포 종양(BPDCN) 환자를 위한 CD123 표적 신규 표적치료제 타그락소푸스프-erzs를 상용화하고 있다. 이와 함께 스템라인은 유럽에서 다발골수종 치료용 XPO1 억제제 셀리넥서를 상용화하고 있다. 회사는 또한 유방암 및 혈액암 적응증에서 각각 엘라세스트란트와 타그락소푸스프의 다수 적응증 확대 연구를 진행하고 있으며, 다양한 고형암과 혈액암을 대상으로 여러 개발 단계에 있는 추가 신약 후보물질의 광범위한 임상 파이프라인을 보유하고
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 09:47 ET Menarini anuncia nuevos datos en la reunión anual de la Sociedad Americana de Oncología Clínica (ASCO) 2026
cáncer hematológico agresivo, en Estados Unidos, Europa y otras regiones del mundo. Además, Stemline comercializa en Europa selinexor, un inhibidor de XPO1 para el mieloma múltiple. La compañía también está realizando múltiples estudios de expansión de marca con elacestrant y tagraxofusp en indicaciones
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:13 ET Menarini Group gibt neue Daten auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) bekannt
hämatologischen Krebserkrankung, in den Vereinigten Staaten, Europa und anderen globalen Regionen. Darüber hinaus vertreibt Stemline in Europa Selinexor, einen XPO1-Inhibitor zur Behandlung des multiplen Myeloms. Das Unternehmen führt außerdem mehrere Studien zur Erweiterung der Indikation mit Elacestrant und Tagraxofusp
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:06 ET Menarini Group annonce de nouvelles données lors de la réunion annuelle 2026 de l'American Society of Clinical Oncology (ASCO)
cellules dendritiques plasmacytoïdes (BPDCN), un cancer hématologique agressif. En outre, Stemline commercialise en Europe le selinexor, un inhibiteur de XPO1 pour le traitement du myélome multiple. La société mène également de multiples études d'extension d'étiquette avec l'élacestrant et le tagraxofusp dans
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:03 ET Menarini Group Anuncia Novos Dados na Reunião Anual da American Society of Clinical Oncology (ASCO) 2026
câncer hematológico agressivo, nos Estados Unidos, Europa e outras regiões globais. Além disso, a Stemline comercializa o selinexor, um inibidor de XPO1 para mieloma múltiplo, na Europa. A empresa também está conduzindo vários estudos de expansão de rótulo com elacestranto e tagraxofusp em indicações
More news about: Menarini Industrie Farmaceutiche Riunite